A Clinical-Genetic (CG) Circulating Tumor DNA (ctDNA)-based Prognostic Model for Predicting Overall Survival (OS) in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Men Treated with Potent Androgen Reception Inhibition (Alliance)
      Google Scholar   
Citation:
J Clin Oncol vol 24 (16_suppl) 5007
Meeting Instance:
ASCO 2024
Year:
2024
Type:
Abstract
Sub type:
Oral
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epreprint
Note:
Methodological:
No
Biospecimen:
No
SDC:
Yes
Parents:
None
Children:
4376  
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
Astellas  
Grants:
U10CA180821, U10CA180882; 5R01-CA256157  
Corr. Author:
 
Authors:
                                 
Networks:
CA136, LAPS-MA036, LAPS-NC010, LAPS-NY016, MN022, NY021   
Study
Alliance-A031201
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: